Treatment Patterns and Costs Of Neoadjuvant Systemic Therapies (NAT) For Early Breast Cancer (EBC): A Retrospective Claims Analysis.
| Autor: | Chen YJ; IMS Health, Alexandria, VA, USA., Santos E; Genentech, Inc., South San Francisco, CA, USA., Schabert V; IMS Health, Alexandria, VA, USA., Antao VP; Genentech, Inc., South San Francisco, CA, USA., De AP; IMS Health, Alexandria, VA, USA., Portera CC; Genentech, Inc., South San Francisco, CA, USA., Wang Y; IMS Health, Alexandria, VA, USA., Kamath T; Genentech, Inc., South San Francisco, CA, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2014 Nov; Vol. 17 (7), pp. A655-6. Date of Electronic Publication: 2014 Oct 26. |
| DOI: | 10.1016/j.jval.2014.08.2393 |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect